NexgenRx Inc.

NexgenRx Inc.

March 24, 2016 16:24 ET

NexgenRx Announces 2015 Annual Results

TORONTO, ONTARIO--(Marketwired - March 24, 2016) - NEXGENRX INC. ("NexgenRx" or the "Corporation") (TSX VENTURE:NXG) is pleased to announce its 2015 annual results.

Revenue for the year ended December 31, 2015 was $4,692,022 with cost of sales $982,012 and gross profit of $3,710,010. The net loss for the year was $188,325 resulting in negative $0.003 per common share.

"The revenue growth of 11% resulted from our focused sales strategy. We continue to expand our sales efforts and create national market awareness," stated Ron Loucks, President and CEO. "We are pleased to announce the development and soft-launch of NexMobile, our mobile app technology now compatible with all iPhone, Android and most other smart devices. Plan members have the ability to check plan design, drug formulary choices, banking information and real time claims submission and adjudication, all from the convenience of their hand-held smart devices," he added.

About NexgenRx

NexgenRx is a growing health benefits management company engaged in the design, management and administration of health benefit plans offered by employers and other plan sponsors for the benefit of their employees and plan members. More information on NexgenRx can be found at

Caution Regarding Forward-Looking Statements - This news release contains certain forward looking statements, including statements regarding the business and anticipated financial performance of the Corporation. These statements are subject to a number of risks and uncertainties. Actual results may differ materially from results contemplated by the forward-looking statements. When relying on forward-looking statements to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and should not place undue reliance on such forward-looking statements.

"Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release."

Contact Information

  • Ronald C. Loucks
    NexgenRx Inc.
    President and CEO
    416.695.3393 x801

    Taba Merrikh
    NexgenRx Inc.
    Director of Finance
    416.695.3393 x803